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OBJECTIVES The aim of our study was to compare the in-hospital and long-term clinical outcomes of
direct coronary stenting with balloon predilation followed by stent placement.
BACKGROUND With improvement in stent designs, the practice of direct stenting without balloon predilation
has become more widespread.
METHODS We analyzed the Mayo Clinic Coronary Intervention data base between January 1, 1995 and
March 5, 1999 and identified 777 patients who were treated with direct stenting (DS) and
3,176 patients treated with balloon angioplasty plus stenting (BA1S).
RESULTS The procedural success rates between the DS and BA1S groups were not significantly
different (96.3% vs. 96.4%). The ability to deliver the stent in a subgroup of patients who had
DS was 95%, with 5% requiring crossover to predilation. Multivariate analysis showed no
significant differences with respect to in-hospital death (odds ratio [OR] 0.9, 95% confidence
interval [CI] 0.5 to 1.8), in-hospital myocardial infarction (OR 0.9, 95% CI 0.6 to 1.2) or
revascularization (OR 0.7, 95% CI 0.4 to 1.5) in the DS compared with the BA1S group.
Long-term outcomes were not significantly different between the DS and BA1S groups. The
procedural duration was significantly shorter in the DS group, and there was a decreased
utilization of contrast agent, balloons and wires.
CONCLUSIONS The in-hospital and long-term clinical outcomes in patients undergoing a coronary inter-
vention are equivalent when comparing stenting without balloon predilation with balloon
angioplasty followed by stenting. Direct stenting is associated with decreased utilization of
contrast agent and equipment and shorter procedure times. A randomized study should be
performed to better determine the impact of this technique on short- and long-term procedural
outcomes. (J Am Coll Cardiol 2000;35:937–43) © 2000 by the American College of Cardiology
The use of coronary stents in interventional cardiology has
increased exponentially over the last decade, both in bailout
and elective settings (1–3). The standard stent implantation
technique involves predilation of the target lesion with a
balloon catheter to allow easy passage of the stent and to
assess the likelihood of complete stent expansion after
deployment (4). With improvement in stent designs, in-
cluding the lower profile and greater flexibility of second-
generation stents, placement of stents without balloon
predilation has become more widespread. This technique is
potentially less traumatic to the vessel wall and may cause
less disruption to distal flow (4,5). This may be particularly
relevant in the presence of thrombus or when treating
degenerated vein grafts (6,7). Despite the increasing fre-
quency of stent deployment without predilation, the imme-
diate procedural and long-term results of this strategy are
not clear. The aim of this study was to compare the
in-hospital and long-term clinical outcomes of direct coro-
nary stenting with the more conventional approach of
balloon predilation followed by stent placement.
METHODS
We performed a retrospective analysis of the Mayo Clinic
Coronary Intervention data base and identified 777 patients
who were treated with direct stenting (DS) and 3,176
patients treated with conventional balloon predilation fol-
lowed by stenting (BA1S) between January 1, 1995 and
March 5, 1999. All patients undergoing percutaneous cor-
onary revascularization at the Mayo Clinic were followed
according to a protocol approved by the Institutional Re-
view Board of the Mayo Clinic and Foundation. This
registry (8) includes baseline and in-hospital demographic,
clinical and angiographic data.
Definitions. Successful stent placement was defined as a
$20% reduction in the lumen diameter stenosis, resulting in
a final residual stenosis within the stent of ,50% by visual
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estimation, with achievement of Thrombolysis in Myocar-
dial Infarction (TIMI) flow grade 3, without the in-hospital
occurrence of death, Q wave myocardial infarction (MI) or
a complication requiring immediate coronary artery bypass
graft surgery (CABG). Acute MI was considered to have
occurred when at least two of the following three criteria
were met: 1) chest pain .30 min in duration; 2) persistent
electrocardiographic changes suggestive of ischemia; or 3)
characteristic elevations in serum creatine kinase levels, with
a corresponding rise in the MB isoform (9). Q wave MI was
defined as two of these criteria with new pathologic Q waves
in the coronary distribution of the stented artery. Thrombus
was considered to be present when one or more lumen-
filling defects in the coronary artery were visualized with
contrast agent present on three sides (10). Dissection was
considered to have occurred when contrast staining was
apparent within the vessel wall (10,11). Dissections were
classified according to the classification system of the
National Heart, Lung, and Blood Institute of the National
Institutes of Health, Bethesda, Maryland. Single-vessel
disease was defined as the presence of a $70% lesion in one
of the three major coronary arteries or their major branches.
Multivessel disease was defined as the presence of a $70%
lesion in a major coronary artery or its major branches and
a $50% lesion in a second coronary artery or its major
branches. The angiographic severity of coronary artery
disease was assessed visually using two orthogonal views.
Lesions were classified according to the modified American
Heart Association/American College of Cardiology lesion
classification scheme by the interventional cardiologist per-
forming the angioplasty procedure, immediately before the
procedure was performed (12). Left ventricular ejection
fractions were calculated using a modified Simpson’s rule
from ventriculography performed in a 30° right anterior
oblique projection.
Intracoronary stent implantation technique. Coronary
angioplasty and intracoronary stent implantation were per-
formed using standard percutaneous techniques (13) via the
femoral, brachial or radial artery. Techniques for implanta-
tion of different stent designs have been described previously
(14). In earlier time periods, 8F guide catheters and over-
the-wire systems were used. In the more recent study
period, rapid-exchange systems and 6F and 7F guide
catheters were more commonly used. The decision whether
to perform predilation was made by the operator. Lesions
that were extremely tortuous or calcified were usually
predilated based on operator judgment regarding the feasi-
bility of stent deliverability. If a decision was made to
proceed without predilation, the stent was usually deployed
at the nominal pressure of the stent balloon, and a high
pressure balloon was subsequently used for dilation within
the stent to 14 to 16 atm. With some of the newer
generation stents, the stent delivery balloon could be in-
flated to 14 atm. With these stents, postdilation with
another balloon was not routinely performed. The first-
generation stents used in the study included the Palmaz-
Schatz (SDS, Johnson & Johnson, Interventional Systems,
Warren, New Jersey), Gianturco-Roubin I (Cook Inc.,
Miami, Florida), Wiktor (Medtronic Inc., Minneapolis,
Minnesota) and biliary stents (Johnson & Johnson, Inter-
ventional Systems). The second-generation stents used in-
cluded the Multilink (Advanced Cardiovascular Systems,
Temecula, California), Microstent II (Arterial Vascular
Engineering, Santa Rosa, California), Crown (Cordis, Mi-
ami, Florida) and Gianturco-Roubin II (Cook Inc.) stents.
Intravascular ultrasound was used at the discretion of the
operator.
Medical therapy. All patients received preprocedural oral
aspirin (325 mg) and intravenous heparin to achieve an
activated clotting time of ;300 s. In patients receiving a
combination of Coumadin (warfarin sodium) and aspirin,
Coumadin was commenced on the evening of the proce-
dure, and intravenous heparin was continued until the
International Normalized Ratio was $2.0. In patients
receiving ticlopidine (commenced in early 1995), the first
dose was administered either immediately before (within
1 h) or during the procedure, with an initial loading dose of
500 mg and 250 mg later that evening and 250 mg twice a
day for two to four weeks after the procedure (15), in
addition to 81 to 325 mg of aspirin daily. After March 1998,
clopidogrel was substituted for ticlopidine and was given as
a loading dose of 300 mg either immediately before (within
1 h) or during the procedure, followed by 75 mg daily for
two weeks. In early 1995, a number of patients received
Coumadin for suboptimal stent deployment, as assessed by
coronary angiography or intravascular ultrasound. Abcix-
imab (a bolus of 0.25 mg/kg body weight followed by a 12-h
infusion of 10 mg/min) was administered immediately
before or during the procedure at the discretion of the
operator. In patients receiving abciximab, heparin was
given, aiming for an activated clotting time between 250
and 300 s.
End points. In-hospital and follow-up events, including
death, Q wave MI, all acute MIs, CABG and repeat
angioplasty of the target vessel, were analyzed.
Follow-up. All patients were interviewed in person or by
telephone six and 12 months after the initial procedure.
Data from visits and hospital periods at the Mayo Clinic
Abbreviations and Acronyms
BA1S 5 balloon angioplasty plus stenting
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
DS 5 direct stenting
MI 5 myocardial infarction
OR 5 odds ratio
SVG 5 saphenous vein graft
TIMI 5 Thrombolysis in Myocardial Infarction
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and other institutions were obtained for review. After
January 1998, the stent deliverability rate was recorded in all
those patients in whom placement of a stent without
predilation was attempted.
Statistical methods. Differences between groups in terms
of clinical and angiographic variables were tested for statis-
tical significance using the Pearson chi-square test for
discrete data or the Student t test for continuous data.
Multivariate logistic regression models were constructed
using the forward selection process for each of the in-
hospital end points. Once a model was constructed, a
dichotomous variable indicating primary stenting was added
to the model. Results are presented as adjusted odds ratios
(ORs) with 95% confidence intervals (CIs). Multivariate
Cox proportional hazards models were developed for each
of the end points recorded during follow-up, again using
forward selection. The adjusted relative risk was obtained by
adding the variable for primary stenting to the model.
Univariate survival curves were calculated using the Kaplan-
Meier method; the log-rank test was used to test for
differences between survival. Based on the sample size and
follow-up of our study, we estimate that for the combined
end point of death, MI and repeat revascularization, we had
statistical power of ;80% to detect a 3% change in the
proportional event-free survival between the two groups at
one year.
RESULTS
Patient characteristics. The clinical characteristics of the
patients in the two groups are described in Table 1. There
was no difference in the mean age, gender, history of
hypercholesterolemia, hypertension, smoking or diabetes
between the two groups. However, more patients had
undergone CABG in the DS group than in the BA1S
group (26.9% vs. 20.7%, p , 0.0001).
Angiographic and procedural characteristics (Tables 2
and 3). There was no difference in the number of diseased
vessels between the two groups, but in the DS group, more
patients with saphenous vein graft (SVG) lesions were
treated (19% vs. 9%, p , 0.001). In the DS group, more
lesions contained thrombus (22% vs. 18%, p , 0.05), and
there was a lower frequency of lesion calcification (34% vs.
47%, p , 0.001), more ostial lesions (29% vs. 21%, p ,
0.001) and a lower incidence of bifurcation lesions treated
(4% vs. 7%, p , 0.01). In addition, there was a less severe
preprocedural lumen diameter stenosis (80.0 6 16.8% vs.
87.3 6 11.0%, p , 0.001) in the DS group.
There was greater utilization of second-generation stents
in the DS group than in the BA1S group (p , 0.001). The
maximal stent deployment pressure was slightly higher in
the DS group (Table 3), but the ultimate inflation pressure
used within the stent after deployment was similar between
the two groups (15.6 6 4.2 vs. 15.9 6 4.6 atm, p 5 NS).
The DS group had fewer dissections after stent implanta-
tion than did the BA1S group (24% vs. 41%, p , 0.001).
However, there was an increase in the percentage of patients
with reduced TIMI flow after stent deployment in the DS
group, perhaps reflecting a higher number of patients with
thrombus-containing lesions and degenerated vein grafts in
this group. The final residual diameter stenosis was similar
between the two groups.
In those patients who underwent stent placement within
a bypass graft, there were trends similar to those of the
overall cohort, with a higher incidence of thrombus-
containing lesions (48% vs. 31%, p , 0.001) and lower
preprocedural stenosis (83.4 6 13.4% vs. 88.4 6 10.8, p ,
0.001) in the DS group. The graft age was significantly
older in the DS group than in the BA1S group (9.6 6 4.6
vs. 8.6 6 4.8 years, p , 0.05). Again, as in the entire cohort,
there were similar balloon inflation pressures within the
stent between the two groups.
In-hospital events (Table 4). The procedural success rates
between the DS and BA1S groups were similar (96.3% vs.
96.4%). The frequency of in-laboratory coronary occlusion
(2.8% vs. 3.0%) and branch occlusion (7.1% vs. 5.8%) was
also similar. Direct stenting was associated with a similar
risk of in-hospital MI in a multivariable analysis (OR 0.9,
95% CI 0.6 to 1.2, p 5 0.47) after adjusting for vein graft
interventions, the number of segments treated, anginal class
Table 1. Clinical Characteristics of the Study Groups
Direct Stenting
(n 5 777)
Stenting With
Balloon Predilation
(n 5 3,176) p Value
Age (years)* 64.8 6 12.2 64.4 6 12.0 NS
Male 70.9% 72.7% NS
Previous bypass surgery 26.9% 20.7% ,0.001
Previous myocardial infarction 53.7% 52.0% NS
Smoking status
Current/former 66.7% 64.3% NS
History of hypercholesterolemia 65.7% 62.0% NS
History of hypertension 62.1% 59.3% NS
History of diabetes 23.3% 21.3% NS
*Continuous variables are presented as the mean value 6 SD.
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and differences in the frequency of use of second-generation
stents. In addition, after adjusting for significant covariates
(see Methods), DS was associated with a similar frequency
of in-hospital death (OR 0.9, 95% CI 0.5 to 1.8, p 5 0.84)
and repeat revascularization (OR 0.7, 95% CI 0.3 to 1.5,
p 5 0.4).
In the subgroup of patients in both groups who under-
went bypass graft interventions, after adjusting for signifi-
cant covariates, DS was associated with a similar in-hospital
mortality (OR 1.1, 95% CI 0.4 to 3.3, p 5 0.77) and risk of
in-hospital MI (OR 0.8, 95% CI 0.7 to 3.0, p 5 0.22).
Follow-up events (Fig. 1). The median follow-up times
available for the patients who successfully survived the
hospital period were 177 days for the DS group and 379
days for the BA1S group. The six-month mortality rates
were 2.2% for the DS group and 2.8% for the BA1S group
(p 5 NS). The frequency of MI during this period was 2.4%
for the DS group and 1.9% for the BA1S group (p 5 NS).
After adjusting for significant covariates, the long-term
adjusted risk ratios for DS were 0.7 for death (95% CI 0.4
to 1.3, p 5 0.28), 0.8 (95% CI 0.6 to 1.2, p 5 0.29) for
death and MI and 0.9 (95% CI 0.7 to 1.2, p 5 0.55) for the
combined end point of death, MI and repeat revasculariza-
tion. In the subgroup of patients with bypass graft inter-
ventions, there was no significant difference in long-term
outcomes for the end points of death and MI or death, MI
and repeat revascularization.
Procedural time, contrast agent used and equipment
utilization. The procedural time in the DS group was
significantly lower than that in the BA1S group (median
1.3 vs. 1.4 h, p , 0.001), as was the fluoroscopy time
(median 25 vs. 20 min, p , 0.0001). The contrast load was
significantly less in the DS group than in the BA1S group
(median 270 vs. 285 ml, p , 0.01). The number of balloons
used (1.7 6 1.6 vs. 2.2 6 1.4, p , 0.001), as well as guide
wires used (2.0 6 1.5 vs. 2.3 6 1.8, p , 0.001), was also
significantly less in the DS group than in the BA1S group.
DISCUSSION
This study demonstrates, for the first time, that the in-
hospital and long-term clinical outcomes in patients under-
Table 2. Baseline Angiographic Characteristics of the Study Groups
Direct Stenting
(n 5 777)
Stenting With
Balloon Predilation
(n 5 3,176) p Value
No. of diseased vessels
1 336 (47%) 1,476 (49%) NS
2 251 (35%) 1,096 (36%)
3 122 (17%) 467 (16%)
Coronary artery stented
LAD 349 (45%) 1,373 (43%) NS
LCx 166 (21%) 761 (24%) NS
RCA 269 (35%) 1,058 (33%) NS
SVG 151 (19%) 291 (9%) ,0.001
Lesion type*
A 45 (6%) 76 (3%) ,0.001
B1 191 (26%) 608 (20%) ,0.01
B2 314 (42%) 1,329 (45%) NS
C 378 (51%) 1,418 (48%) NS
Unknown 70 (9%) 274 (9%) NS
Thrombus present before stent procedure
Definite/probable 142 (22%) 486 (18%) ,0.05
Calcium present
In artery 330 (47%) 1,663 (57%) ,0.001
In stenosis 244 (34%) 1,411 (47%) ,0.001
Stent on bend
None/mild 207 (55%) 1,387 (54%)
Moderate/severe 189 (45%) 1,130 (46%)
Percent stenosis before procedure† 80.0 6 16.8 87.3 6 11.0 ,0.001
Ostial lesion 122 (29%) 594 (21%) ,0.001
Branch involvement 378 (51%) 1,638 (53%) NS
Bifurcation lesion 31 (4%) 225 (7%) ,0.01
Proximal angulation 449 (61%) 1,871 (61%) NS
*According to American College of Cardiology/American Heart Association lesion classification. †Data are presented as the mean value 6 SD.
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary artery; RCA 5 right coronary artery; SVG 5 saphenous vein graft.
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going a coronary intervention are equivalent using the novel
technique of DS compared with the more conventional
technique of balloon angioplasty followed by stenting. This
similar outcome was achieved despite more high risk char-
acteristics in DS group, including a higher frequency of
previous CABGs, vein graft interventions and thrombus at
the treatment site. These outcomes were achieved with
shorter procedure times and decreased utilization of contrast
agent and equipment in the DS group.
Direct stenting has become increasingly popular with the
availability of more deliverable stents. This study, however,
includes our early experience using the first-generation
Palmaz-Schatz and Gianturco-Roubin stents, although the
majority of DS procedures employed second-generation
stents such as the ACS Multilink stent. This technique has
been advocated previously in a select group of patients with
a lesion length ,12 mm, in the absence of calcification or
tortuosity (4). In this study, the safety of DS in a larger
group of patients is demonstrated, including those with vein
grafts and thrombus-containing lesions. Patients with cal-
cified lesions were also treated with DS in our study,
although those with very heavy calcification were not. Direct
stenting in this study was performed at the discretion of the
operator; lesions within vein grafts and those containing
thrombus were commonly selected for the technique. The
DS group also had a lower preprocedural stenosis as
compared with the BA1S group, reflecting the concern that
tighter stenoses may be more difficult to cross without
balloon predilation, and thus may lead to a greater risk of
stent dislodgment from the delivery balloon. Other poten-
tial concerns associated with the technique of DS include
the potential for stent loss and embolization, the possibility
Table 3. Procedural Characteristics of the Study Groups
Direct Stenting
(n 5 777)
Stenting With
Balloon Predilation
(n 5 3,176) p Value
Stent type
Palmaz-Schatz 21.5% 39.7%
Gianturco-Roubin I 3.7% 11.0%
Gianturco-Roubin II 2.1% 4.2%
Wiktor 0% 1.0%
Crown 3.2% 1.8%
AVE 5.7% 8.8%
ACS 41.5% 17.7%
NIR 12.1% 3.7%
Other 10.2% 12.1%
Second-generation stent 556 (72%) 1,375 (43%) ,0.001
Stent diameter (mm) 3.4 6 0.5 3.3 6 0.5 NS
Maximal pressure during stent
deployment (atm)
10.1 6 4.1 8.1 6 3.3 ,0.001
Diameter stenosis after stenting 3.7 6 11.2% 4.3 6 10.7% ,0.001
Dissection after stenting 179 (24%) 1,283 (41%) ,0.001
Inflation within stent after
deployment
Maximal pressure (atm) 15.6 6 4.2 15.9 6 4.6 NS
No. of inflations 2.8 6 2.7 2.7 6 2.2 NS
Reduced TIMI flow (0/1) after
stenting
38 (5%) 99 (3%) ,0.05
Data are presented as the mean value 6 SD or number (%) of patients.
TIMI 5 Thrombolysis in Myocardial Infarction.
Table 4. In-Hospital Events
In-Hospital Events
Direct Stenting
(n 5 777)
Stenting With
Balloon Predilation
(n 5 3,176) p Value
Adjusted OR (95% CI)
for Direct Stenting vs.
Balloon Predilation
Death 11 (1.4%) 53 (1.7%) NS 0.9 (0.5–1.8)
MI 52 (6.7%) 210 (6.6%) NS 0.9 (0.6–1.2)
CABG/repeat PTCA 9 (1.1%) 49 (1.5%) NS 0.7 (0.4–1.5)
Data are presented as the number (%) of patients.
CABG 5 coronary artery bypass graft surgery; CI 5 confidence interval; MI 5 myocardial infarction; OR 5 odds ratio; PTCA 5 percutaneous transluminal coronary
angioplasty.
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of incomplete stent expansion, compromised lesion and
distal vessel visualization and subsequent difficulty with
exact stent positioning. Optimal guiding support is also
necessary if DS is attempted.
It may be hypothesized that DS may improve clinical
outcomes, partly by decreasing the number of balloon
inflations and deflations and decreasing ischemia time (4).
Direct stenting is potentially less traumatic to the vessel wall
and may cause less ischemia, dissection and disruption to
distal flow. This may be particularly the case when throm-
bus is present or when treating aging vein grafts (6).
Residual dissections after stenting have been associated with
an increased risk of major adverse cardiac events (16), and
the frequency of dissections after stent implantation in this
study was lower in the DS group. Moreover, the use of
stents in a bailout situation after severe dissection has been
associated with a worse outcome (16), supporting the
possibility that predilation may be harmful in a small
number of patients. This potential risk is diminished with
the technique of DS. In contrast to these potential benefits,
the frequency of reduced TIMI flow after the procedure in
this study was increased in the DS group, perhaps because
of the treatment of more vein grafts and lesions containing
thrombus. This decreased TIMI flow in the DS group did
not lead to excess in-hospital complications, but is concern-
ing nonetheless and warrants further investigation.
In this nonrandomized study, patients selected for DS
were significantly more likely to require treatment of a
bypass graft, and ;20% of the DS group underwent a
bypass graft intervention. Previous reports have suggested
that SVG stenting without predilation may decrease proce-
dural complications such as distal embolization, no-reflow
phenomenon and periprocedural MI (6). These complica-
tions are more common in vein grafts as compared with
native vessel interventions (17), occurring in up to 15% of
procedures (18). In our study, the group treated with DS
had significantly more thrombus present and older vein
grafts, representing a group at higher risk for distal embo-
lization and periprocedural MI. Despite this, treatment of
SVG lesions with DS instead of balloon predilation had a
similar rate of in-hospital events and similar long-term
clinical outcomes. A randomized study is needed to further
assess the impact of DS in this high risk subgroup of
patients.
The technique of DS has potential advantages in terms of
shortened procedural time, decreased radiation and contrast
load received by the patient and decreased cost of the
procedure. In our study, both the contrast load used and the
procedural time were decreased by DS. These decreases may
be clinically important, especially in the high risk group of
patients. In addition, we found a decrease in the number of
balloons used in the DS group, potentially leading to a lower
overall procedural cost.
Study limitations. We are not able to comment on the
overall success rate of stent delivery in our cohort, as this
study was retrospective, and for the initial part of the study,
we were unable to ascertain how frequently patients in the
DS group crossed over and required predilation. This
information was recorded after January 1998, and subse-
quent to this, the stent deliverability rate in the 406 patients
in whom DS was attempted was 95%. The success rate of
DS would be expected to improve as stent technology is
further refined. However, the patients treated with DS in
this study were selected because of an operator’s decision
regarding their “suitability” for DS, and the general appli-
cability of this technique needs further evaluation. Variabil-
ity of the success of DS between different stent designs may
occur, and evaluation in each stent type is important. It
should also be noted that the DS group had a lower
preprocedural stenosis as compared with the BA1S group.
Another limitation is that routine angiographic follow-up
was not performed, and the frequency of angiographic
restenosis in the two groups is unknown. However, the
clinical event rate at six months was similar between the two
groups.
Conclusions. This study demonstrates that the in-hospital
and long-term clinical outcomes in patients undergoing a
coronary intervention are equivalent using the novel tech-
nique of DS as compared with the more conventional
technique of BA1S. The outcome was similar, even though
the DS group included a higher risk group of patients.
There was decreased utilization of contrast agent and
equipment and shorter procedure time in the DS group. A
randomized study is needed to further assess the ability of
this technique to reduce the risk of short- and long-term
procedural complications and resource utilization.
Reprint requests and correspondence: Dr. David R. Holmes,
Jr., Division of Cardiovascular Diseases, Mayo Clinic, 200 First
Street SW, Rochester, Minnesota 55905. E-mail: holmes.david@
mayo.edu.
Figure 1. Kaplan-Meier curves showing event-free survival for the
combined end point of death, MI and revascularization in the DS
versus the BA1S group.
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